Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution.

Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. (“YD Bio USA”) entered into a Master Strategic Alliance Agreement (the “Agreement”) with YC Biotech Co., Ltd. (“YC Biotech”) on February 24, 2026.

TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced it has entered into a binding Letter of Intent (the “LoI”) to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology Co., Ltd. ("SSMC"), a Taiwan-based dendritic cell immunotherapy platform.

Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery.

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a focused, catalyst-driven strategy for 2026, and plans to transition from platform validation to accelerated asset-level clinical and commercial development, subject to regulatory feedback and resource availability.

Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics.

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No.